Henry Ford receives a $ 250,000 grant to help reduce the differences in prostate cancer among black men

The Henry Ford Cancer Institute has received a $ 250,000 grant from Pfizer Global Medical Grants and the American Cancer Society to help reduce the differences in prostate cancer among black men. While all men are at risk of prostate cancer, black men are at increased risk of developing and dying from prostate cancer.

Black men tend to develop prostate cancer at a younger age, have more advanced disease when diagnosed, and are twice as likely to die from prostate cancer as men of other races and ethnic groups. These differences are complex and multifactorial, and contribute factors ranging from access to care to genetics, the environment, lifestyle, and more. With the support of Pfizer and the American Cancer Society, in addition to our experience serving the various communities in Detroit and Southeast Michigan, at Henry Ford we are uniquely positioned to reduce these disparities with the goal of eliminating them completely one day. “

Eleanor M. Walker, MD, director of breast radiation oncology and medical director of integrative services at the Henry Ford Cancer Institute

In a highly competitive process, each applicant was asked to provide solutions to local problems across the cancer continuum. Pfizer and ACS also made grants to health systems in Massachusetts, Florida, Georgia, Washington, DC, and Pennsylvania, with Henry Ford Health System being the only beneficiary in Michigan.

“Eliminating prostate cancer disparities is critical to promoting health equity in Detroit and Southeast Michigan. We look forward to tracking the success of this project as it identifies the factors contributing to these disparities and effective avenues designed to reduce or eliminate them. ” “said Kathleen Goss, Ph.D., vice president of cancer control for the North Central Region of the American Cancer Society.

Henry Ford recently started a project that aims to dramatically improve the representation of the black community and other minorities in cancer clinical trials. This community-based research initiative is funded by a Genentech grant and is known as the Participatory Action Project for Access to Clinical Trials (PAACT). It is a collaboration with the Detroit Community-Academic Urban Research Center (Detroit URC) to address various barriers to trust and participation in clinical trials. Dr. Walker, who is co-investigating the PAACT project, believes these initiatives will fuel health system efforts to eradicate cancer disparities within black and other minority communities, thereby creating greater equity in health care.

Depending on the stage, prostate cancer can be treated with active surveillance, surgery, radiation therapy, hormone therapy, chemotherapy, or immunotherapy. Henry Ford Health System is a national leader in minimally invasive robotic surgery for prostate cancer and performed some of the first robotic prostate surgeries in the country. Henry Ford has been using robotic techniques since 2001 to improve outcomes for people with prostate and other cancers. Minimally invasive robotic procedures are often more effective and lead to fewer complications, so patients can recover more quickly after surgery.

Comments are closed.